Oncopeptides
1.81 SEK
-6.60 %
Less than 1K followers
ONCO
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
-6.60 %
+31.92 %
+6.47 %
-62.33 %
-68.79 %
+8.36 %
-67.44 %
-97.25 %
-93.73 %
Oncopeptides is a biotechnology company developing drugs for difficult-to-treat hematological diseases. The company uses its PDC platform to develop peptide-linked drugs that selectively deliver cytotoxic agents into cancer cells. The company has drugs for commercialization, and has several drug candidates in development. Oncopeptides was founded in 2000 and is headquartered in Stockholm.
Read moreMarket cap
715.47M SEK
Turnover
15.73M SEK
Revenue
71.12M
EBIT %
-315.87 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
27.8
2026
Interim report Q2'26
5.11
2026
Interim report Q3'26
All
Webcasts
Press releases
3rd party
ShowingAll content types
Oncopeptides signs agreement with Salus for distribution and commercialization of Pepaxti in Central and Eastern Europe
Bulletin from the Annual General Meeting in Oncopeptides
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
